An observational study in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Active, not recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by United Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Pulmonary Arterial Hypertension by United Therapeutics — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · United Therapeutics.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is one of 5 that started in 2017, is one of 6 observational ones, and was the 41st registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics is open now, in 12 countries. Recruiting first, the newest first:
United Therapeutics · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2017.
This study's planned enrollment of 300 is above the median of 107 across 182 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 33 across the 45 interventional studies, 71 across the 6 observational. Of the 40 that completed or were terminated, 28 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
2 of the studies in Pulmonary Arterial Hypertension by United Therapeutics that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT03045029United TherapeuticsADAPT - A Patient Registry of the Real-world Use of Orenitram® | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
Patients are eligible if they have been receiving Orenitram for 182 or fewer days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible for the registry if:
EXCLUSION CRITERIA
Patients are ineligible for the registry if:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
Drug: Oral treprostinil
Sustained-release oral tablets for TID administration
Also known as: Treprostinil diethanolamine, Treprostinil diolamine
Real-world use and tolerability of Orenitram in new starts and prostacyclin transition patients
Time frame: Baseline to Week 78
To assess treatment-related outcomes during routine clinical care.
eg, 6-Minute Walk Distance \[6MWD\], World Health Organization \[WHO\] Functional Class \[FC\]
Time frame: Baseline to Week 78
To observe the development, timing, severity, frequency, and treatment of prostacyclin-related adverse events (AEs) of interest
Time frame: Baseline to Week 78
Use of concomitant medications
Time frame: Baseline to Week 78
To evaluate information on clinical titration schedules implemented for transition to and from alternative prostacyclin-class therapies
Time frame: Baseline to Week 78
Healthcare resource utilization trends
Time frame: Baseline to Week 78
Health-related quality of life in PAH and treatment satisfaction
Time frame: Baseline to Week 78
To evaluate reasons for discontinuation of Orenitram
Time frame: Baseline to Week 78
To evaluate titration and dosing schedules of Orenitram
Time frame: Baseline to Week 78
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2017 (actual). Primary completion is estimated for Mar 2027, 116 months after the start.
Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 116 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →